ID   LAM1
AC   CVCL_W912
SY   LAM-1; Lam-1
DR   cancercelllines; CVCL_W912
DR   Cosmic; 1054587
DR   Wikidata; Q54901909
RX   PubMed=17199440;
RX   PubMed=25675381;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Ile85Serfs*33 (c.249_252delGTCT) (p.Leu83fs); ClinVar=VCV000016693; Zygosity=Unspecified (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:28958; NUP93; Simple; p.Gln15Ter (c.43C>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:9822; RAD51B; Simple; p.Gln270Ter (c.808C>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly154del (c.460_462delGGC); Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Left subcarinal lymph node; UBERON=UBERON_8480055.
ST   Source(s): PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 10,11
ST   D16S539: 8,12
ST   D18S51: 15
ST   D3S1358: 15,17
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 12
ST   FGA: 19,22
ST   TH01: 9.3,10
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 19-12-24; Version: 16
//
RX   PubMed=17199440; DOI=10.1089/thy.2006.16.1293;
RA   Copland J.A. 3rd, Marlow L.A., Williams S.F., Grebe S.K.G., Gumz M.L.,
RA   Maples W.J., Silverman V.E., Smallridge R.C.;
RT   "Molecular diagnosis of a BRAF papillary thyroid carcinoma with
RT   multiple chromosome abnormalities and rare adrenal and hypothalamic
RT   metastases.";
RL   Thyroid 16:1293-1302(2006).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. 3rd;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//